Aficamten – Medxy AI

Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy

By MedXY 09/10/2025

A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).

Cardiology news Pathology & Lab Medicine Specialties

VO2 Recovery Time as a Novel Cardiac Performance Biomarker: Insights from the SEQUOIA-HCM Trial

By MedXY 09/05/2025

This article elucidates VO2T12.5% as a new, practical oxygen uptake recovery measure reflecting cardiac function and prognosis in heart failure and obstructive hypertrophic cardiomyopathy, validated in robust clinical cohorts including the SEQUOIA-HCM trial.

Cardiology Clinical Updates news Specialties

Aficamten: A Breakthrough Oral Therapy for Obstructive Hypertrophic Cardiomyopathy Across Symptom Severity

By MedXY 08/17/2025

Aficamten significantly improves exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM), demonstrating robust efficacy and safety in both mildly and severely symptomatic patients.

Cardiology news Specialties

Aficamten in Obstructive Hypertrophic Cardiomyopathy: Durable 48-Week Benefits and Insights on Combination Therapy

By MedXY 08/17/2025

Aficamten shows sustained obstruction relief, symptom improvement, and favorable cardiac remodeling over 48 weeks in obstructive hypertrophic cardiomyopathy, with safe discontinuation of disopyramide possible.